Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. - Wikidata - wikimedia - TriplyDB

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.

http://www.wikidata.org/entity/Q37924077

about

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration Genetic risk, ethnic variations and pharmacogenetic biomarkers in age-related macular degeneration and polypoidal choroidal vasculopathy Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis.Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management.Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population.Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab.Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis.Identifying Common Genetic Risk Factors of Diabetic Neuropathies.Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.Risk factors and biomarkers of age-related macular degeneration.A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward?Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.

P2860

Q27015781-DFE325DC-D362-438E-8C0C-C26A7DFC501F Q33645265-83D67E66-EEEA-4335-B3BA-ACAF30522F49 Q33823849-75CCE4F3-C7B5-44F7-B3FC-4975A2E040A8 Q34384420-2BE63240-42D8-4FF5-BA6B-F60DD495A149 Q34556444-FEA50082-16B7-4777-9A8E-B261FAC279A0 Q34620551-C7A4DCB1-C7CF-4CE7-AFDB-0B6D78BB8651 Q34781693-88722293-7D25-4305-90C9-FC139C795050 Q36350410-8AF6C8A2-2619-456D-B038-6EEF450C972C Q36445951-EE8E6B32-9ACE-4ED9-A2AB-0FDD9ACD711B Q36727716-22B1EFF2-6C1A-462E-A91F-35622C280B33 Q37166529-86530CAF-D9EA-426A-B7C5-26DCB77B241B Q37266897-E13DF134-C0F4-4DDA-928C-F0865BCA38C0 Q38134807-2452879D-9A0A-4D8C-A302-329D16F70887 Q38245807-F8061C28-0400-4A73-8E45-F35768D5794C Q38527798-3952D9EF-FD91-47AC-A201-7256FF07ECC3 Q38827325-E658D2C7-F7D1-4C73-81A4-215BF8377087 Q38828895-38D92F47-26F9-40F5-AB5A-AA7DEA659822 Q41504310-E71BE013-B796-4A81-8AD6-F513CDBF4E8D Q41833477-7B855184-1D89-4103-862E-5951E6653BA8 Q42136459-595D5D56-6639-4E4B-A95A-6B191DE2FC05 Q43364243-35AD4FF8-8379-44F1-A6E7-9EF8FA1D82E6 Q44097181-C9128849-D215-4B42-BEB4-4111DEECEFF8 Q49176127-38F07DF5-EDFF-4FAA-A75F-D54834075DA0 Q52559837-E0D45EF1-9CF0-4B0E-BB3C-F413E5E68482

P2860

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.

http://www.wikidata.org/entity/Q37924077

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Association between high-risk ...... -related macular degeneration.

@en

Association between high-risk ...... -related macular degeneration.

@nl

type

label

Association between high-risk ...... -related macular degeneration.

@en

Association between high-risk ...... -related macular degeneration.

@nl

prefLabel

Association between high-risk ...... -related macular degeneration.

@en

Association between high-risk ...... -related macular degeneration.

@nl

P1433

Q37924077-A5DE3141-7F34-42CA-84AA-B19BDBC79EF4

P1476

Q37924077-2A15BE47-6FB4-42DA-8EDA-FE7F744B4B4B

P2093

Q37924077-0DEA81B5-45D4-4E1B-8151-83CB366C0B06

Q37924077-50CC544D-9B9D-4578-989E-C77C831346D3

Q37924077-53463F06-8F49-42A2-9E09-52EBC4DBD753

Q37924077-C3F1621E-B8B6-4E92-BCF8-EFA53EABA83B

Q37924077-CB1E5D77-C13B-48E0-862B-3AA9C5E0481E

Q37924077-D67089D0-4922-4DBC-B935-AAE44C13FA51

Q37924077-E213F6FD-9D05-4C3C-B506-81AD350070B6

Q37924077-E7C7B67F-B259-4856-AE0E-4CB21B8328BE

Q37924077-F2AD290B-001D-4E06-9E50-DA19C6771BBC

P304

Q37924077-FCDB27A4-BBB1-4596-A205-14724C398ED6

P31

Q37924077-9519AE90-59A8-4AB8-B089-63450CF93CD3

P356

Q37924077-4F5AB73F-AC3D-4643-A673-93CEA120446F

P433

Q37924077-D4F5E33D-9BDC-406A-80B5-516D07A34F2E

P478

Q37924077-ECC6FB8D-3966-4C80-B029-7AAD71C072C9

P50

Q37924077-67778A80-5981-48FE-BA42-91929741052F

Q37924077-90D78E1C-16EA-49FC-817F-60C0CCA741EE

P577

Q37924077-167EE553-63D9-4B45-BC95-E9CAAD645013

P698

Q37924077-CD8DF890-BA82-406A-BA85-4280BB0CB6E6

P921

Q37924077-DA53E9BF-AF11-49CF-8928-B9EF036F0CCA

P356

IAE.0B013E31822A2C7C

P1433

P1476

Association between high-risk ...... -related macular degeneration.

@en

P2093

Allen C Ho

http://www.w3.org/2001/XMLSchema#string

Anton Orlin

http://www.w3.org/2001/XMLSchema#string

Ashlee N Godshalk

http://www.w3.org/2001/XMLSchema#string

Audun Lier

http://www.w3.org/2001/XMLSchema#string

Brian Kaderli

http://www.w3.org/2001/XMLSchema#string

Carl D Regillo

http://www.w3.org/2001/XMLSchema#string

Gary Brown

http://www.w3.org/2001/XMLSchema#string

Richard S Kaiser

http://www.w3.org/2001/XMLSchema#string

Woohyok Chang

http://www.w3.org/2001/XMLSchema#string

P304

4-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IAE.0B013E31822A2C7C

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Dwight Stambolian

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21878851

http://www.w3.org/2001/XMLSchema#string

P921